Introduction of 9 - 12 month courses of multidrug - resistant tuberculosis therapy will increase the effectiveness of treatment and reduce the total number of anti-tuberculosis
drugs during the course of treatment and save funds that can be used to treat more patients.
Since these provisions only relate to whistleblower actions in relation to the covered entity, disclosure
of protected health information to expose malfeasant conduct by another person, such as knowledge gained
during the
course of treatment about an individual's illicit
drug use, would not be protected activity.